AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.64, payable on Friday, Feb.

AbbVie stock jumped 4.7% to close at 183.90. Shares have spent the better part of this month trapped below their 200-day line, according to MarketSurge. Across all products, AbbVie generated $15.1 ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

That's a good analogy for AbbVie, which must continually create new products to replace treatments whose patents expire. The great news is that AbbVie has seemingly done that with its new ...

AbbVie has been named a Top Socially Responsible ... considerations like the environmental impact of the company's products and services, as well as the company's efficiency in terms of its ...

AbbVie cautions that these forward-looking statements ... competition from other products, difficulties inherent in the research and development process, adverse litigation or government action ...

AbbVie CEO Robert Michael will soon add the role of board chairman to his résumé. Michael, who became CEO of the North Chicago-based pharmaceutical giant last summer, will assume duties as ...

the immune-disease drug that was once Abbvie's top-selling product, as well as slowing sales of the company's aesthetic products such as Botox.

Danaher, Recursion Pharmaceuticals, Moderna, Thermo Fisher Scientific, AbbVie, Vertex Pharmaceuticals, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to ...

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...